Latest News

Unleashad

European_Commission.svg

TILT won a grant for a 2.5 M€ (~$ 2.9M) project, entitled UNLEASHAD, from the European Commission EIC SME Instrument. The grant will be used to perform a Phase 1 clinical trial with the company’s lead drug, TILT-123. Read the press release here.

Latest News

Upcoming Events

Please contact our business development team to meet us at the following events:

June 13-16th 2022
San Diego (CA), U.S.A.
28-29th September 2022
Malmö, Sweden
28th September - 1st of October 2022
New York City (NY), U.S.A.
24-26th October 2022
Leipzig, Germany